Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 11.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 311,701 shares of the company’s stock after purchasing an additional 33,205 shares during the period. Geode Capital Management LLC owned 0.93% of Reviva Pharmaceuticals worth $564,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Reviva Pharmaceuticals in the fourth quarter valued at about $25,000. Drive Wealth Management LLC purchased a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, EMC Capital Management lifted its stake in shares of Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after buying an additional 26,134 shares during the period. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $0.87 on Friday. The firm has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $1.37. Reviva Pharmaceuticals Holdings, Inc. has a 1-year low of $0.49 and a 1-year high of $4.28. The stock has a market cap of $40.52 million, a PE ratio of -0.78 and a beta of 0.05.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, sell-side analysts expect that Reviva Pharmaceuticals Holdings, Inc. will post -0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RVPH. HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. D. Boral Capital reiterated a “buy” rating and set a $8.00 price target on shares of Reviva Pharmaceuticals in a research report on Thursday, April 24th. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, January 10th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Reviva Pharmaceuticals has an average rating of “Buy” and a consensus price target of $10.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.